Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Cancer Pain × Cannabidiol × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 4 Seizures 3 Lennox Gastaut Syndrome 2 Epilepsies, Myoclonic 2 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Liver Neoplasms 1 Liver Cirrhosis 1 Glioblastoma 1 Gallbladder Neoplasms 1 Colonic Neoplasms 1 Cancer Pain 1 Behavior 1

Interventions

Oxycodone 8 Morphine 4 Fentanyl 4 resiniferatoxin 3 nabiximols 3 Naloxone 2 tanezumab 1 rofecoxib 1 naloxegol 1 fulranumab 1 cannabichromene 1 alvimopan 1 Venlafaxine Hydrochloride 1 Ultracet 1 Tapentadol 1 Standard of Care 1 Radiation 1 Propofol 1 Nerve Growth Factor 1 Methadone 1 Memantine 1 Inosine Monophosphate 1 Electroencephalography 1 Duration of Therapy 1 Dronabinol 1 Cannabidiol 1 Antibodies 1 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06533657 2026-03-12

UTOPIA-1

ZYUS Life Sciences Inc.

Phase 2 Active not recruiting

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡